Rocco Amendolara

Pubblicazioni

Titolo Pubblicato in Anno
IFN-α neutralizing antibodies distinguish LADA from early-onset type 1 diabetes THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 2025
Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study DIABETES, OBESITY AND METABOLISM 2024
Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes EXPERT OPINION ON INVESTIGATIONAL DRUGS 2024
No differences in kidney function decline between people with type 2 diabetes starting a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist: a real-world retrospective comparative observational study CLINICAL THERAPEUTICS 2024
Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes DIABETES/METABOLISM RESEARCH AND REVIEWS 2023
Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a six months follow-up study: The CoVaDiab study I DIABETES/METABOLISM RESEARCH AND REVIEWS 2022
Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19. a systematic review and meta-analysis INTERNAL AND EMERGENCY MEDICINE 2021

Gruppi di ricerca

Intervento farmacologico inibente la differenziazione delle cellule mieloidi verso un fenotipo calcificante
Molecular and pathophysiological heterogeneity of autoimmune diabetes: implications for precision medicine

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma